Arco Pharma Private Limited

Arco Pharma Private Limited, incorporated on March 22, 1983, is a private unlisted company based in Mumbai, Maharashtra, India. The company is classified under the Corporate Identification Number (CIN) U24230MH1983PTC029602 and is registered at the Registrar of Companies, Mumbai. Its authorized share capital is ₹10,000,000, with a paid-up capital of ₹5,000,000. The registered office is located at 60/70, Ranvir Building, 2nd Floor, Room No.15, Princess Street, Mumbai, Maharashtra, 400002.

The company specializes in the manufacturing of pharmaceuticals, medicinal chemicals, and botanical products. As of March 29, 2024, Arco Pharma employed 11 individuals. The ownership structure is predominantly held by promoters, with 92.83% shareholding, while the public holds 4.10%, and others account for 3.07%.

Arco Pharma Private Limited operates manufacturing facilities in Mumbai, Maharashtra. Specific details regarding plant locations, capacities, and specializations are not publicly disclosed. The company's focus is on the production of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. However, comprehensive information about the manufacturing processes and capacities is not readily available.

The key executives of Arco Pharma Private Limited include:

• Amichand Punamchand Jain: Director, appointed on March 22, 1983.

• Rakesh Kumar Amichand Jain: Director, appointed on April 1, 2001.

Information regarding the roles of Chief Executive Officer (CEO) or Chief Financial Officer (CFO) is not publicly available.

Arco Pharma Private Limited's export activities, as per TransData Nexus proprietary trade data, include:

• Total Export Value: $271,000 USD

• Total Shipments: 23

• Products Exported: 2 across 2 therapeutic categories

• Top 5 Products:

• Aminophylline: $248,000 (Rank #2, 4.2% market share)

• Niacin: $23,000 (Rank #10, 0.6% market share)

• Top 3 Categories:

• Respiratory & OTC: 91.6%

• Lipid & Metabolism: 8.4%

• Portfolio Concentration: Top 5 products = 100%

Specific details regarding regulatory filings, approvals, and market access status in the United States, European Union, United Kingdom, Australia, and Japan are not publicly disclosed. The company's export activities are primarily focused on the Respiratory & OTC and Lipid & Metabolism therapeutic categories.

Arco Pharma Private Limited's export data indicates a focus on the Respiratory & OTC and Lipid & Metabolism therapeutic categories. Specific information regarding the company's penetration into African, Latin American, and Southeast Asian markets, as well as WHO prequalification status, is not publicly available.

Arco Pharma Private Limited's export activities are concentrated in the Respiratory & OTC and Lipid & Metabolism therapeutic categories, with Aminophylline and Niacin being the top exported products. The company's portfolio concentration is 100% on these top 5 products, indicating a focused product strategy. However, specific details regarding geographic diversification, concentration risk, and strategic direction are not publicly disclosed.

Specific information regarding Arco Pharma Private Limited's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history is not publicly available. The company's export data does not provide insights into its presence in the U.S. market.

Details regarding Arco Pharma Private Limited's WHO prequalification, EU Good Manufacturing Practice (GMP) certificates, and European Directorate for the Quality of Medicines & HealthCare (EDQM) status are not publicly available. The company's export data does not indicate compliance with these international standards.

Specific information regarding Arco Pharma Private Limited's Central Drugs Standard Control Organisation (CDSCO) manufacturing licenses, state drug controller approvals, and export No Objection Certificates (NOCs) is not publicly available. The company's export data does not provide insights into its compliance with Indian regulatory requirements.

There are no publicly available records of Form 483 observations, warning letters, or import alerts issued to Arco Pharma Private Limited. The company's export data does not indicate any recent regulatory actions.

Arco Pharma Private Limited operates in the pharmaceutical manufacturing sector, focusing on finished pharmaceutical formulations in the Respiratory & OTC and Lipid & Metabolism therapeutic categories. Specific information regarding its top competitors, market share comparison, and head-to-head analysis is not publicly available.

Arco Pharma Private Limited's key differentiators include its focus on finished pharmaceutical formulations in the Respiratory & OTC and Lipid & Metabolism therapeutic categories, with Aminophylline and Niacin being the top exported products. The company's portfolio concentration on these top 5 products indicates a specialized product strategy. However, specific details regarding unique strengths, competitive advantages, and product portfolio distinctions are not publicly disclosed.

Arco Pharma Private Limited's strategic direction appears to be focused on the manufacturing and export of finished pharmaceutical formulations in the Respiratory & OTC and Lipid & Metabolism therapeutic categories. The company's portfolio concentration on its top 5 products suggests a specialized approach. However, specific information regarding its current strategic direction, such as emphasis on generics, specialty drugs, biosimilars, or Contract Development and Manufacturing Organization (CDMO) services, as well as future outlook, is not publicly available.

Arco Pharma Private Limited's export data indicates a focus on the Respiratory & OTC and Lipid & Metabolism therapeutic categories, with Aminophylline and Niacin being the top exported products. The company's portfolio concentration on these top 5 products suggests a specialized product strategy. However, specific information regarding the company's overall track record, export volume and consistency, and reliability indicators is not publicly available.

Importers considering Arco Pharma Private Limited as a supplier should verify the following certifications:

• FDA Facility Registration: To ensure compliance with U.S. regulatory standards.

• WHO-GMP Certification: To confirm adherence to World Health Organization Good Manufacturing Practices.

• EU GMP Certification: To verify compliance with European Union Good Manufacturing Practices.

• ISO Certification: To assess the company's adherence to international quality management standards.

Verification can be conducted through official regulatory bodies' websites or by requesting documentation directly from the supplier.

Importers should undertake the following steps to ensure a comprehensive evaluation of Arco Pharma Private Limited:

• Verify Regulatory Certifications: Confirm the validity of FDA, WHO-GMP, EU GMP, and ISO certifications.

• Assess Manufacturing Capabilities: Evaluate the company's manufacturing facilities, capacities, and compliance with international standards.

• Review Financial Health: Analyze the company's financial statements to assess stability and reliability.

• Check Export History: Review the company's export records to ensure consistency and reliability in supply.

• Conduct Background Checks: Investigate the company's history, reputation, and any past regulatory issues.

Red flags to watch for include expired or invalid certifications, inconsistent financial records, and a history of regulatory non-compliance. Recommended pre-order checks involve requesting up-to-date certifications, recent financial statements, and references from previous clients.